Navigation Links
IGI Laboratories, Inc. Announces Change To Its Board Of Directors
Date:7/24/2014

BUENA, N.J., July 24, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has accepted  Damian Finio's resignation from its Board of Directors.  Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and under the terms of his acceptance of his new position, Mr. Finio will be unable to continue in his role as Director for IGI Laboratories, Inc.  The effective date of his resignation will be August 11, 2014.  The Company has begun a search to replace Mr. Finio on its Board of Directors. 

About IGI Laboratories, Inc.

IGI Laboratories is a specialty generic drug development and manufacturing company. Our mission is to be a leading player in the specialty generic prescription drug market.

IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "believe", "target", "estimated," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Actual results may differ materially from these expectations. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Logo - http://photos.prnewswire.com/prnh/20130827/MM70487LOGO


'/>"/>
SOURCE IGI Laboratories, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
2. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
3. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
4. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
5. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
6. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
7. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
8. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
9. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
10. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
11. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, WI-based RF ... hospitality and education, is celebrating its 30th year in business this month. , ... manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his years in ...
(Date:8/17/2017)... ... August 17, 2017 , ... Recently ... once more by being among Houston’s first plastic surgeons to offer boutique and ... surgery care without disrupting busy schedules and maintaining the utmost discretion in the ...
(Date:8/17/2017)... Angeles, CA (PRWEB) , ... August 17, 2017 , ... ... partners Mark Hardiman, John Mills and Harry Nelson. This is the third consecutive year ... for Nelson. Hardiman and Nelson were both recognized for expertise in Health Care Law ...
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited ... CO, at Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on ... radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of ...
(Date:8/17/2017)... ... 17, 2017 , ... Dr. Charles W. Grimsley’s new book ... paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed with ... forgiveness, through a progressive journey toward healing. This book will help readers learn ...
Breaking Medicine News(10 mins):